Physician profile
Sevan Karadolian Duff
NPI 1659571305
$2,386.42
in general payments reported to CMS, 2019-2025
10 companies · $274 in 2025
The $274 reported for 2025 was more than what 82% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $611 · 2020: $125 · 2022: $528 · 2023: $235 · 2024: $613 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,121.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $566.97 | 2019-2024 | Jardiance |
| Abiomed | $365.90 | 2024-2025 | Impella |
| Astrazeneca Pharmaceuticals Lp | $359.53 | 2020-2023 | Andexxa |
| Janssen Pharmaceuticals, INC | $233.65 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $199.59 | 2022-2024 | Lifevest |
| Kestra Medical Technology Services, INC. | $151.82 | 2025 | Assure Wcd |
| Allergan, INC. | $147.27 | 2019 | |
| Gilead Sciences, INC. | $126.00 | 2024 | Veklury |
| Boston Scientific Corporation | $119.24 | 2019 | |
| Novartis Pharmaceuticals Corporation | $116.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sevan Duff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.